Post by BNP Paribas CIB

Angelini Pharma has announced an agreement to acquire Catalyst Pharmaceuticals for US$4.1 billion.   Angelini Pharma, the pharmaceutical division of Angelini Industries, is a leading Italian specialty pharmaceutical company focused on central nervous system (CNS) treatments.   The acquisition of Catalyst Pharmaceuticals aligns with Angelini Pharma’s ambition to boost its commercial presence in the US market and its strategy to become a leading player for the treatment of rare neuromuscular diseases.   The transaction marks the largest ever cross border transaction, by deal value, by an Italian healthcare company.   BNP Paribas is acting as Financial Advisor and Lead Financing Bank to Angelini Pharma underscoring our long-term support of European healthcare clients in their cross-border growth ambitions.   The transaction is expected to close in Q3 2026.